Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.
Deutsche Bank sets Sarepta stock target at $136, cites risks
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Sarepta initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting ...